Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine vs 3+7 in Newly Diagnosed AML with NPM1 or IDH1/2 Mutations
NCT07664839Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, azacitidine in acute myeloid leukemia (AML). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07664839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07664839.